

Prostate disease Screening Program in Novohopersk area of Voronezh region ("Novohopersk")

Submission date 26/08/2014	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 22/09/2014	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 29/05/2020	Condition category Cancer	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Prostate cancer in men is very common. However, it usually develops slowly with the first signs of the disease being problems with urinating once the prostate is large enough to press against the urethra (the tube that takes urine from the bladder to the penis). If caught early, this form of cancer is very treatable and many countries have screening programmes to detect it. Early stage prostate cancer can be diagnosed using a blood test called the prostate-specific antigen (PSA) test. An increased amount of PSA can, in some cases, happen due to prostate cancer. In Russia, the number of men with prostate cancer is rather high, is increasing and has a high mortality rate (high number of men dying from the disease). The high mortality rate is a result of a large number of cases not being diagnosed until the disease is at an advanced stage and has already spread to other parts of the body. A PSA test cannot be used to definitely detect the condition as it can also be raised due to, for example, non-cancerous growths and urinary tract diseases. However, Russia healthcare services do need a method to detect prostate cancer earlier. Here, we are going to look at how possible it is to have a PSA test screening programme in Russia, how well it would perform and whether it would be worth spending money on such a programme. We want to estimate how many men in a particular region have the disease, at what stage the cancer is detected and how useful a PSA test might be in screening for the disease, particularly for men aged 45-54 (as this age group is less likely to be included in PSA screening programmes). We also want to calculate how much a screening programme would cost and whether it would be worth the money involved, taking into account the relatively short male life expectancy in Russia.

Who can participate?

Men aged 45-65 in the Novohopersk area of the Voronezh Region (VO)

What does the study involve?

After gathering clinical information for all the participants (from the state medical compulsory insurance system), they are invited for a PSA test at a study centre. They then have a physical examination to check for prostate cancer and undergo a transrectal ultrasound scan (TRUS) to see how large the prostate gland is. In those cases where prostate cancer is found, the affected

participants undergo further tests to see how far the cancer has progressed (pelvic MRI, bone scintigraphy and possible abdominal, peritoneal and thoracic CT scans).

What are the possible benefits and risks of participating?

The major benefits to participants taking part in the study are a high quality medical examination and early detection of prostate cancer. The risks involve infections and other complications and side-effects of biopsy.

Where is the study run from?

1. Federal State Research Scientific Institute of Urology of the Health Ministry of Russia (Russia)
2. Healthcare Department of Voronezh Region (Russia)
3. MBHI Novohaporsk Central Regional Hospital (Russia)
4. VO BHI Voronezh Regional Clinical Hospital N1 (Russia)

When is the study starting and how long is it expected to run for?

December 2013 to January 2015.

Who is funding the study?

1. Federal State Research Scientific Institute of Urology of the Health Ministry of Russia (Russia)
2. Healthcare Department of Voronezh Region (Russia)
3. MBHI Novohaporsk Central Regional Hospital (Russia)
4. VO BHI Voronezh Regional Clinical Hospital N1 (Russia)
5. LLC Beckman Coulter (Russia)

Who is the main contact?

Professor Oleg Apolikhin
Apolikhin.oleg@gmail.com

Contact information

Type(s)

Scientific

Contact name

Prof Oleg Apolikhin

Contact details

3d Parkovaya str
Moscow
Russian Federation
105425
+7 (0) 499 367 75 87
apolikhin.oleg@gmail.com

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N/A

Study information

Scientific Title

Population-based screening study: feasibility and effects evaluation of prostate cancer (PCa) screening in Russia and evaluation of economic efficacy

Acronym

SPiNAV

Study objectives

It is hypothesized that screening decreases mortality.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Local ethical committee, 28/10/2013, ref. N98

Study design

12-months population-based study

Primary study design

Interventional

Secondary study design

Single-centre

Study setting(s)

Other

Study type(s)

Screening

Participant information sheet

Not available in web format, please use the following contact details to request a patient information sheet: Federal State Budget Scientific Research Institute of Urology, Ministry of Health Care of Russian Federation, Moscow 105425 3d Parkovaya 51, phone +7 499 367 75 87, email: apolikhin.oleg@gmail.com or international.uro@gmail.com

Health condition(s) or problem(s) studied

Prostate disease/prostate cancer

Interventions

1. All involved patients fill questionnaires (IPSS/QoL, SWOP - calculator 1,2 and 4)
2. Blood serum PSA level detection
3. Digital rectal examination (DRE)

4. Transrectal ultrasound scan (TRUS)
5. Pelvic MRI (1 month after prostate biopsy)
6. Bone scintigraphy (PSA level \geq 20 ng/ml)
7. Thorax CT, X ray
8. Abdominal, peritoneal and thoracic CT scan (by indications)

Intervention Type

Other

Phase

Not Applicable

Primary outcome measure

1. Prostate cancer detection rate (%)
2. Prostate cancer detection rate in age groups (%)
3. Prostate cancer detection rate by stages (TNM system)
4. PSA sensitivity, specificity, PPV and NPV (%)
5. Prostate cancer detection costs in one patient in rubles
6. Localized clinically significant (treatment needed) prostate cancer detection costs in one patient in rubles

Secondary outcome measures

1. Questionnaires (IPSS/QoL, SWOP calculator 1,2 and 4) - results registered in points and percents
2. Blood serum PSA level detection (PSA) - ng/ml
3. Digital rectal examination (DRE) - positive/negative
4. Transrectal ultrasound scan (TRUS), (positive/negative) including determination of prostate volume in cc
5. Prostate biopsy (standard 12 core) with morphological examination of tissue samples
6. Cancer staging - registered in TNM system

Overall study start date

01/12/2013

Completion date

01/01/2015

Eligibility**Key inclusion criteria**

Men aged 45-65

Participant type(s)

Patient

Age group

Adult

Sex

Male

Target number of participants

3715

Key exclusion criteria

Prostate cancer in anamnesis

Date of first enrolment

01/12/2013

Date of final enrolment

01/01/2015

Locations

Countries of recruitment

Russian Federation

Study participating centre

3d Parkovaya str

Moscow

Russian Federation

105425

Sponsor information

Organisation

Federal State Research Institute of Urology of Ministry of Health Care of Russia (Russia)

Sponsor details

3d Parkovaya str., 51

Moscow

Russian Federation

105425

+7 (0) 499 165 84 37

international.uro@gmail.com

Sponsor type

Government

Website

<http://uro.ru>

ROR

<https://ror.org/01p8ehb87>

Funder(s)

Funder type

Other

Funder Name

Federal State Research Institute of Urology of the Ministry of Health Care of Russia, Moscow (Russia)

Funder Name

Healthcare Department of Voronezh Region (Russia)

Funder Name

MBHI Novohaporsk Central Regional Hospital (Russia)

Funder Name

VO BHI Voronezh Regional clinical hospital N1 (Russia)

Funder Name

LLC Beckman Coulter (Russia)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration